CBIO vs GYRE
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 12, 2026
CBIO
GYRE
Investment Advisor Scores
GYRE
AI Analyst Insights
Detailed Metrics Comparison
| Metric | CBIO | GYRE | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 78.125 | Tie |
| PEG Ratio | 0 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 0.0% | -2.1% | CBIO |
| Earnings Growth | 0.0% | 166.2% | GYRE |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 31.4/100 | 42.6/100 | GYRE |
| Profit Margin | 0.0% | -19.3% | CBIO |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | SELL | HOLD | GYRE |
Relative Price Performance (Last 90 Days)
Current Technical Phase
CBIO
MarkupPrice above SMA50, rising 50-day trend (0.8% over 20 days), RSI 58
GYRE
MarkupPrice above SMA50, rising 50-day trend (3.7% over 20 days), RSI 52
Fundamentals Snapshot
| Metric | CBIO | GYRE |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -7.4 | -28.6 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.0% |
| Gross Margin | 1.0% | 0.9% |
| Operating Margin | -14.3% | -0.5% |
| EPS | -0.14 | -0.20 |
| Dividend Yield | — | — |